Valeant Canada is actively seeking to in-license late-stage clinical and/or commercialized products in the following key disease target areas. Neurology Infectious Diseases Dermatology Specialty Pain Management Parkinson’s Disease Epilepsy Multiple Sclerosis Huntington’s Disease ALS   Hepatitis HIV SARS RSV   Psoriasis Eczema Acne Rosacea Actinic Keratoses Squamous Cell Carcinoma Anti-fungals (topical) Sleep Disorders   Valeant’s Collaboration Process When a product is evaluated at Valeant it passes through five inter-related stages.  As an integrated pharmaceutical organization Valeant’s management team is capable of gathering robust information and resources to efficiently come to decisions promptly and to advance the collaboration process into the launch stage.